Bronchiectasis Therapeutic Market Size

Bronchiectasis Therapeutic Market size is expected to cross USD 3 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of bronchiectasis therapeutic was over USD 500 Million. The global market for therapies for bronchiectasis is anticipated to increase at a faster rate due to the rising prevalence of respiratory illnesses. The primary driver of the market growth is the accessibility of inexpensive medications, or off-label generics, in both developed and developing nations. An additional piece of evidence supporting the significant contribution of chronic respiratory disorders to premature morbidity and death is the fact that reports state that approximately 545 million people worldwide, or 7·4% of the total population, currently live with a chronic respiratory ailment.

One major factor propelling the bronchiectasis therapeutic market is the accessibility of inexpensive off-label generics in both developed and developing countries. The supply of affordable off-label generics in both developed and developing countries is a major factor propelling the market for bronchiectasis treatment's revenue growth. The same active ingredient is found in both branded and generic pharmaceuticals, although generics are more affordable than novel pharmaceuticals.